Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer

Journal of Thoracic Disease

Volumn 6, Issue 4, 2014, Pages 387-398

  Palmer, Joshua D ^a   Zaorsky, Nicholas G ^a,b   Witek, Matthew ^a   Lu, Bo ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

biomarkers; Lung cancer; novel therapies; toxicity

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BEVACIZUMAB; CRIZOTINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; MUCIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALK GENE; ARTICLE; BRAF GENE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; EGFR GENE; GENE; GENE FUSION; GENE MUTATION; GENE TRANSLOCATION; HER2 GENE; HIGH RISK POPULATION; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; LIVIN ALPHA GENE; LUNG CANCER; LUNG TOXICITY; MDM2 GENE; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE K RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PI3K GENE; PREDICTIVE VALUE; RADIATION INDUCED TOXICITY; RADIATION INJURY; RADIATION PNEUMONIA; RADIOSENSITIVITY; TP54I3 GENE; TRACHEOESOPHAGEAL FISTULA; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84900498863     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.12.04     Document Type: Article

References (69)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-56.
4. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's lung cancer mutation consortium (LCMC). J Clin Oncol 2011;29:CRA7506.
5. Rowinsky EK. The erB family: targets for therapeutic development against cancer and therapeutic strategies sing monocloncal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004;55:433-57.
6. Decker RH, Lynch TJ. Unmet challenges in the use of novel agents in locally advanced non-small-cell lung cancer. J Clin Oncol 2012;30:582-4.
7. Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of nonsmall- cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
8. Sato M, Shames DS, Gasdar AF, et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2:327-43.
9. Oldenhuis CN, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008;44:946-53.
10. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
11. Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013;31:2173-81.
12. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-smallcell lung cancer. J Clin Oncol 2013;31:1097-104.
13. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003;54:73-87.
14. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor resceptor signaling athway in lung cancers. Int J Cancer 2006; 118:257-62.
15. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
16. Wu K, House L, Liu W, et al. Personalized targeted therapy for lung cancer. Int J Mol Sci 2012;13:11471-11496.
17. Verweij J, de Jonge M. Multitarget tyrosine kinase inhibition: [and the winner is]. J Clin Oncol 2007;25:2340-2.
18. Aréchaga-Ocampo E, Villegas-Sepulveda N, Lopez-Urrutia E, et al. (2013). Biomarkers in Lung Cancer: Integration with Radiogenomics Data, Oncogenomics and Cancer Proteomics-Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer, Dr. Cesar Lopez (Ed.), ISBN: 978-953-51-1041-5, InTech, DOI: 10.5772/53426.
19. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada clinical trials group study BR.21. J Clin Oncol 2008;26:4268-75.
20. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is DRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010;28:4769-77.
21. Ausborn NL, Le QT, Bradley JD, et al. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2012;83:e453-64.
22. Rose-James A, Sreelekha TT. Molecular markers with predictive and prognostic relevance in lung cancer. Lung Cancer Int 2012;2012:12.
23. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006;24:1689-99.
24. Lambrechts D, Lenz HJ, de Haas S, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013;31:1219-30.
25. Withers HR. The four R's of radiotherapy. Adv Radiat Biol 1975;5:241-7.
26. Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of nonsmall- cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
27. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol 2007;25:2243-7.
28. Sun Y, Moretti L, Giacalone NJ, et al. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol 2011;6:699-706.
29. Lu B, Mu Y, Cao C, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004;64:2840-5.
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
31. Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010;15:411-21.
32. Cavallo F, De Giovanni C, Nanni P, et al. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011;60:319-26.
33. Suzuki K, Kyuichi K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor ß2 (IL-12Rß2), IL-7R, and stromal foxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013;31:490-8.
34. Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013;20:22-31.
35. Rüttinger D, Winter H, van den Engel NK, et al. Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist 2010;15:112-8.
36. Topalian SL, Hodi SF, Brahmer JR, et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
37. Tahara H, Sato M, Thurin M, et al. Emerging concepts in biomarker discovery; the US-Japan workshop on immunological molecular markers in oncology. J Transl Med 2009;7:45.
38. Romero P. Current state of vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 2008;9 Suppl 1:S28-36.
39. Schaue D, Ratikan JA, Iwamoto KS, et al. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012;83:1306-10.
40. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013;105:256-65.
41. Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at rsl1982073: T869C of the TGFbeta1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009;27:3370-8.
42. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-52.
43. Keedy VL, Argeaga CL, Johnson DH. Does gefitinib shorten lung cancer survival? Chaos redux. J Clin Oncol 2008;26:2428-30.
44. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-12.
45. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomized, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
46. Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference? J Clin Oncol 2013;31:1081-8.
47. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer. J Clin Oncol 2008;326:2450-6.
48. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:303-10.
49. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 2010;363:1693-703.
50. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
51. Castañon E, Bosch-Barrera J, López I, et al. Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. J Transl Med 2013;11:13.
52. Raben D, Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome? J Clin Oncol 2012;30:3909-12.
53. Buettner R, Wolf J, Thomas, RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013;31:1858-65.
54. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76:S70-6.
55. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76:S10-9.
56. Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research.Int J Radiat Oncol Biol Phys 2006;66:1281-93.
57. Hartsell WF, Scott CB, Dundas GS, et al. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Am J Clin Oncol 2007;30:368-76.
58. Zhao L, Wang L, Ji W, et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-smallcell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys 2009;74:1385-90.
59. Fu XL, Hong H, Bentel G, et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001;50:899-908.
60. Huang EX, Hope AJ, Lindsay PE, et al. Heart irradiation as a risk factor for radiation pneumonitis. Acta Oncol 2011;50:51-60.
61. D'Errico MP, Grimaldi L, Petruzzelli MF, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys 2012;82:e239-46.
62. Dienstmann R, Braña I, Rodon J, et al. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011;16:1729-40.
63. Lind JS, Senan S, Smit EF. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. J Clin Oncol 2012;30:e104-8.
64. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-48.
65. Bradley JD, Paulus R, Komaki R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy ± cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617. J Clin Oncol 2013;31:abst 7501.
66. Cannon DM, Mehta MP, Adkison JB, et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 2013;31:4343-8.
67. Baker R, Han G, Saranqkasin S, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys 2013;85:190-5.
68. Bongers EM, Botticella A, Palma DA, et al. Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. Radiother Oncol 2013;109:95-9.
69. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85:444-50.